Video

Rapid Readouts: TROPHY-U-01 Cohort 1 Final Results

Author(s):

Cora Sternberg, MD, FACP, Weill Cornell Medicine

Related Videos
Joshua Linscott, MD, PhD
Terence W. Friedlander, MD,
Bernard H. Bochner, MD, FACS
Roger Li, MD
Roger Li, MD, genitourinary oncologist, Moffitt Cancer Center
Antonio Cigliola, MD
Joshua Linscott, MD, PhD, urologic oncology fellow, Moffitt Cancer Center
Rashad Nawfal, MD
Roger Li, MD
Brigatinib in NF2-Related Schwannomatosis with Progressive Tumors
Related Content
Dr Thomas Powles, of the Barts Cancer Institute Biomedical Research Centre
August 28th 2024

Enfortumab Vedotin Plus Pembrolizumab Approved in Europe for Metastatic Urothelial Cancer

Oncology Unplugged
August 7th 2024

Park and Grivas Expand on Treatment Updates in Bladder Cancer

Srikala Sridhar, MD, of Princess Margaret Cancer Centre
August 22nd 2024

Enfortumab Vedotin Plus Pembrolizumab Approved in Canada for Advanced Bladder Cancer

Oncology Unplugged
July 24th 2024

Park and Sonpavde on Sacituzumab Govitecan Plus Enfortumab Vedotin in Metastatic Urothelial Cancer

FDA
August 14th 2024

FDA Approval Sought for UGN-102 in Low-Grade, Intermediate-Risk NMIBC

urothelial cancer - stock.adobe.com
August 12th 2024

China’s NMPA Grants Breakthrough Therapy Designation to 9MW2821 in Advanced Urothelial Cancer